Review article · 2025 · Open access
ABS0715 THE RISK OF MALIGNANCY AND MAJOR ADVERSE CARDIOVASCULAR EVENTS WITH THE USE OF JANUS KINASE INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF REAL-WORLD EVIDENCE
Annals of the Rheumatic Diseases, 84, 2009–2010 · Published 1 June 2025 · DOI 10.1016/j.ard.2025.06.1584
In brief
“ABS0715 THE RISK OF MALIGNANCY AND MAJOR ADVERSE CARDIOVASCULAR EVENTS WITH THE USE OF JANUS KINASE INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF REAL-WORLD EVIDENCE” is a 2025 review article by M. Haider and 2 co-authors, published in Annals of the Rheumatic Diseases. OpenAlex counts 1 citations as of 19 November 2026. It is open access under a CC BY-NC-ND licence: the full text is free to read at Annals of the Rheumatic Diseases.
- Citations
- 1
- Most cited in
- 2026 (1)
- Field-weighted impact
- 0.11
- Authors
- 3
Abstract
Background: Tofacitinib is the first Janus Kinase Inhibitor (JAKi) approved for treating adults with rheumatoid arthritis (RA). Recently, its use has been linked to an increased risk of major adverse cardiovascular events (MACE) and malignancy. These concerns emerged from the findings of the oral surveillance trial, which is a mandated post-authorization safety trial designed to assess the risk of MACE and malignancy in JAKi versus Tumor Necrosis Factor inhibitors (TNFi) patients [1]. We aimed to investigate whether these concerns have been replicated in real world settings. Objectives: Our objective was to quantify the risk of MACE, overall malignancies, and non-melanoma skin cancer (NMSC) associated with the use of JAKi versus TNFi in RA patients in daily clinical practice settings. Methods: A systematic literature review was conducted using four databases (Medline, Embase, Scopus and Web of Science). Databases were searched from inception until March 30 th , 2024. Only observational cohort studies that assessed the risk of MACE and malignancy in JAKi versus TNFi in adult RA patients were retrieved. A quantitative data synthesis was carried out using a random effects model with the inverse variance method to calculate the pooled hazard ratios (HR) with 95% confidence interval (CI). Risk of bias in eligible studies was assessed using Risk of Bias In Non-randomized Studies of Interventions (ROBINS-1) tool created by the Cochrane collaboration [2]. This review was registered with the International Prospective Register of Systematic Reviews (PROSPERO registration ID: CRD42024525148). Results: Thirty-five studies describing a total of more than 350,000 patients were eligible for our study. Most patients were female and above 50 years of age on average. Geographically, 14 studies were from Asia, 13 from Europe, seven from North America, and one from Oceania. Tofacitinib was evaluated solely against TNFi in 14 studies. Baricitinib and Upadacitinib were included in 16 and six studies, respectively. Around half of the studies were judged as low risk of bias based on the ROBINS-I tool. The results of data synthesis for all patients showed a HR of 0.95 [0.84–1.07] (Figure 1), 0.97 [0.90–1.04] (Figure 2), and 1.17 [1.07–1.28] for the risk of MACE, malignancy and NMSC in JAKi versus TNFi patients respectively. The results of data synthesis for only high-risk patients showed a HR of 0.92 [0.70-1.21] and a HR of 1.16 [0.89-1.52] for the risk MACE and malignancy in JAKi versus TNFi patients respectively. Conclusion: JAKi were not associated with increased risk of MACE or malignancy when compared to TNFi in a real-world setting. However, JAKi were associated with a small increased risk…
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Haider, M., Alalwan, O., & Harris, H. (2025). ABS0715 THE RISK OF MALIGNANCY AND MAJOR ADVERSE CARDIOVASCULAR EVENTS WITH THE USE OF JANUS KINASE INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF REAL-WORLD EVIDENCE. Annals of the Rheumatic Diseases, 84, 2009–2010. https://doi.org/10.1016/j.ard.2025.06.1584
MLA 9
Haider, M., et al. “ABS0715 THE RISK OF MALIGNANCY AND MAJOR ADVERSE CARDIOVASCULAR EVENTS WITH THE USE OF JANUS KINASE INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF REAL-WORLD EVIDENCE.” Annals of the Rheumatic Diseases, vol. 84, 2025, pp. 2009–2010. https://doi.org/10.1016/j.ard.2025.06.1584.
Chicago
Haider, M., Osama Alalwan, and H. Harris. 2025. “ABS0715 THE RISK OF MALIGNANCY AND MAJOR ADVERSE CARDIOVASCULAR EVENTS WITH THE USE OF JANUS KINASE INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF REAL-WORLD EVIDENCE.” Annals of the Rheumatic Diseases 84: 2009–2010. https://doi.org/10.1016/j.ard.2025.06.1584.
Harvard
Haider, M., Alalwan, O. and Harris, H. (2025) ‘ABS0715 THE RISK OF MALIGNANCY AND MAJOR ADVERSE CARDIOVASCULAR EVENTS WITH THE USE OF JANUS KINASE INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF REAL-WORLD EVIDENCE’, Annals of the Rheumatic Diseases, 84, pp. 2009–2010. doi:10.1016/j.ard.2025.06.1584.
IEEE
M. Haider, O. Alalwan, and H. Harris, “ABS0715 THE RISK OF MALIGNANCY AND MAJOR ADVERSE CARDIOVASCULAR EVENTS WITH THE USE OF JANUS KINASE INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF REAL-WORLD EVIDENCE,” Annals of the Rheumatic Diseases, vol. 84, pp. 2009–2010, 2025, doi: 10.1016/j.ard.2025.06.1584.
BibTeX
@article{haider2025risk,
title = {{ABS0715 THE RISK OF MALIGNANCY AND MAJOR ADVERSE CARDIOVASCULAR EVENTS WITH THE USE OF JANUS KINASE INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF REAL-WORLD EVIDENCE}},
author = {Haider, M. and Alalwan, Osama and Harris, H.},
journal = {Annals of the Rheumatic Diseases},
year = {2025},
volume = {84},
pages = {2009--2010},
doi = {10.1016/j.ard.2025.06.1584},
url = {https://doi.org/10.1016/j.ard.2025.06.1584}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- rheumatoid arthritis
- JAK inhibitors
- tofacitinib
- baricitinib
- upadacitinib
- major adverse cardiovascular events
- cancer risk
- non-melanoma skin cancer
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Haider, M., Alalwan, O., & Harris, H. (2025). ABS0715 THE RISK OF MALIGNANCY AND MAJOR ADVERSE CARDIOVASCULAR EVENTS WITH THE USE OF JANUS KINASE INHIBITORS IN PATIENTS WITH RHEUMATOID ARTHRITIS: A SYSTEMATIC REVIEW AND META-ANALYSIS OF REAL-WORLD EVIDENCE. Annals of the Rheumatic Diseases, 84, 2009–2010. https://doi.org/10.1016/j.ard.2025.06.1584
How many times has this paper been cited?
1 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Annals of the Rheumatic Diseases: sign in and open the full text from this page.
Who wrote this paper?
M. Haider, Osama Alalwan, H. Harris.
What is the DOI of this paper?
10.1016/j.ard.2025.06.1584, permanently at https://doi.org/10.1016/j.ard.2025.06.1584. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.